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The down-regulation of protein kinase C (PKC) subspecies in KM3 cells (a pre-B, pre-T cell line) has been examined. 
The PKC from KM3 cells was resolved into two subspecies, type II (mainly /III) and type III (a), upon hydroxyapatite 
column chromatography. Biochemical and immunocytochemical analysis revealed that, when these cells were treated with 
l2-O-tetradecanoylphorbol I3-acetate (TPA), the time course of down-regulation of the PKC subspecies was different; 
type II PKC was translocated and depleted from the cell more quickly than type III enzyme. The results suggest that 
each PKC subspecies plays a different role in the cellular response to TPA and probably to other external stimuli. 
Protein kinase C; Enzyme subspecies; Down-regulation 
1. INTRODUCTION 
Tumor-promoting phorbol esters elicit a variety 
of biological responses in tissues and cultured cells 
(reviews [1,2]). PKC has been generally accepted as 
a major receptor for phorbol esters [3,4], which 
stimulate its rapid translocation from the cytosol 
to the membrane and subsequent depletion in 
many cell types [5,6]. At that time PKC is pro- 
teolytically activated by calpain [7-91. Long-term 
stimulation by TPA often causes either differentia- 
tion or proliferation of various cell lines. 
Molecular cloning studies indicate that PKC ex- 
ists as a family of subspecies; four cDNA clones 
named LY-, ,&I-, PII- and y-PKC were initially found 
(review [lo]). Recently, another group of cDNA 
clones designated 6-, E- and I_-PKC have been 
isolated [ll]. On the other hand, rat brain PKC 
can be resolved by hydroxyapatite column 
chromatography into three fractions, types I-III 
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Calf thymus HI histone was prepared as in [7]. 
Phosphatidylserine and 1,2-diolein were from Serdary Research 
Laboratories. [y-“P]ATP was purchased from Amersham. 
TPA was obtained from Chemicals for Cancer Research. 
2.2. Cells 
Abbreviations: PKC, protein kinase C; FPLC, fast protein The human pre-B, pre-T leukemic cell line, KM3 [19], was 
liquid chromatography; TPA, 12.0tetradecanoylphorbol kindly provided by Dr J. Minowada (Hayashibara Biochemical 
13-acetate Laboratories, Inc.) and cultured in RPMI 1640 (Flow) sup- 
[ 12,131. Analysis of the PKC subspecies expressed 
in COS 7 cells transfected by y-, ,&@I +PII)- and a- 
cDNAs shows that hese encode type I, II and III 
PKC, respectively [14]. Some cell lines, such as 
NIH 3T3 [15], A431 [16] and COS 7 cells [13], con- 
tain only type III (CY) PKC, but a variety of other 
tissues [ 171 and cell types, including T lymphocytes 
[ 181, co-express various PKC subspecies. Such 
tissue- and cell-specific expression of PKC 
subspecies suggests that each member of the en- 
zyme family has a different function in cell 
responses to external stimuli. This paper describes 
a biochemical and immunocytochemical analysis 
of the PKC subspecies and their differential mode 
of down-regulation in the clonal pre-B, pre-T cell 
line, KM3 [19]. 
2. MATERIALS AND METHODS 
2.1. Materials and chemicals 
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plemented with 5% fetal calf serum (Gibco), 2 mM glutamine 
and penicillin-streptomycin (50 U/ml and 50 pg/ml, respective- 
ly) at 37°C in 5% COZ. In all experiments cells were used at a 
density of 1 x lo6 cells/ml. 
2.3. Partial purification of PKC from KM3 cells 
KM3 cells (approx. 2 x 10s cells) were suspended in 4 ml of 
20 mM Tris-HCI (pH 7.5) containing Or25 M sucrose, 10 mM 
EGTA, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride 
and 100 pg/ml leupeptin. The cells were lysed by sonication us- 
ing three 15-s bursts, and centrifuged at 100000 x g for 30 min. 
The supernatant from this centrifugation was designated 
‘cytoplasmic fraction’. The pellet was re-sonicated in 2 ml of 
the same buffer containing 1% (v/v) Triton X-100 and re- 
centrifuged as above. The supernatant from this centrifugation 
was designated ‘particulate fraction’. These crude fractions 
were separately applied to a 4 ml DE-52 column equilibrated 
with 20 mM Tris-HCl (pH 7.5) containing 0.5 mM EDTA, 
0.5 mM EGTA and 10 mM 2-mercaptoethanol (buffer A). 
After washing with 2 column volumes of buffer A, followed by 
3 column volumes of buffer A containing 20 mM NaCI, PKC 
was eluted batchwise with 3 column volumes of buffer A con- 
taining 120 mM NaCl. The eluate was resolved by 
chromatography on a hydroxyapatite column connected to an 
FPLC system as described [14]. Using this chromatography 
system, type I, II and Ill PKCs were eluted at approx. 90, 100 
and 150 mM potassium phosphate, respectively. 
2.4. Assay of PKC 
The enzyme was assayed with calf thymus Hl histone as a 
phosphate acceptor in the presence of phosphatidylserine 
(8 pg/ml), diolein (0.8 gg/ml) and 0.3 mM Ca’+ as in [14]. 
Blank incubation was performed by replacing CaClz with 
0.5 mM EGTA without addition of lipids. 
2.5. Immunocytochemical analysis of PKC subspecies in KM3 
cells 
After treatment, cells were fixed in acetone for 20 min at 
room temperature and washed twice with phosphate-buffered 
saline. Aliquots of these cells (approx. 2 x 10’ cells) were 
cytocentrifuged onto gelatin-coated glass slides. Cells on the 
slide were permeabilized by incubation in 0. I % Triton X-100 
for 20 min at room temperature. After washing, cells were in- 
cubated overnight at 4°C with appropriate polyclonal anti-PKC 
antibodies containing 0.02% normal human serum. The 
polyclonal antibodies, designated CKpVSfll-a, CKpVSflll-a and 
CKpVlcu-a, were prepared against the sequence-specific 
oligopeptides SYTNPEFVINV [type II VI) PKC, residues 
661-6711, SFVNSEFLKPEVKS [type II @II) PKC, residues 
660-6731 and VYPANDSTASQDVANR [type Ill (cu) PKC, 
residues 4-191, respectively. These antibodies were purified by 
column chromatography on anti-IgG Sepharose and on the cor- 
responding peptide coupled to Sepharose. The localization of 
PKC subspecies in the cells was visualized using an anti-rabbit 
immunoglobulin streptavidin/biotin-peroxidase immunostain- 
ing kit (Biogenex) according to the manufacturer’s instructions, 
except that samples were incubated with biotin-conjugated anti- 
rabbit immunoglobulins and streptavidin at 4°C for 2 and 1 h, 
respectively. 3,3’-Diaminobenzidine was employed as substrate 
for the peroxidase. 
TIME (MIN) 
Fig. 1. Time course of PKC translocation and down-regulation 
in KM3 cells. KM3 cells were treated with 50 nM TPA for the 
indicated times, and crude fractions were prepared and assayed 
as described in section 2. PKC activity was defined as the kinase 
activity measured in the presence of phospholipid and Ca*’ 
minus that detected in the absence of phospholipid and with 
Ca’+ replaced by 0.5 mM EGTA. PKC activity in (0) 
cytoplasmic and (3) particulate fractions. 
3. RESULTS 
Fig. 1 shows the time course of down-regulation 
of PKC in KM3 cells in response to treatment with 
50 nM TPA. At time 0 more than 98% of PKC ac- 
tivity was found in the cytoplasmic fraction. PKC 
activity in this fraction was decreased by approx. 
50% at 2 min after treatment with TPA. At 15 min 
the soluble PKC activity was undetectable. Some 
of the PKC activity was recovered in the par- 
ticulate fraction, with maximal activity at 5 min. 
After 60 min PKC activity remained only in the 
particulate fraction (approx. 15% of total PKC ac- 
tivity at time 0). 
Immunocytochemical staining of PKC during 
the treatment with TPA is demonstrated in fig.2. 
KM3 cells are stained strongly by CKpVS,BII-a 
(anti$II) as well as CKpVla-a (anti-a), but very 
weakly by CKpVSPI-a (anti-PI). No staining was 
observed with antibody against y-PKC. The result 
indicates that KM3 cells express cr-, PII- and a 
small quantity of PI-, but not y-PKC subspecies. 
This conclusion was supported by immunoblotting 
analysis. In untreated control cells, PII- and LY- 
PKC were both located predominantly in the 
cytoplasm (fig.2A,E). At 5 min after treatment 
with TPA (50 nM) the staining intensity of PII- 
PKC was markedly decreased compared with the 
intensity observed at time 0, while staining of Q- 
PKC was of the same intensity as at time 0. When 
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Fig.2. Time course of immunocytochemical localization of PKC subspecies in KM3 cells. KM3 cells were treated with 50 nM TPA 
for the indicated times. Cells were then rapidly cooled by addition of ice-cold medium, and after centrifugation, stained as described 
in section 2. (A-D) Staining by CKpVIw-a, (E-H) staining by CKpVSfiII-a. (A,E) At time 0, (B,F) 2 min. (C,G) 5 min. (D,H) 180 min 
after treatment with TPA. 
these cells had been treated for 3 h, the staining in- 
tensity of both (Y- and PII-PKC had decreased, 
although some granular staining was observed in 
the cytoplasm and perinuclear regions of some 
cells. PI-PKC disappeared in a manner essentially 
similar to that of /3II-PKC, although the staining 
intensity was very weak. The disappearance of 
PKC subspecies was not due to death of the cells 
as judged by trypan blue exclusion. 
The immunocytochemical analysis described 
above suggests that the time course of depletion of 
PKC subspecies is different. This possibility was 
examined further biochemically by isolating PKC 
subspecies from TPA-treated cells by hydrox- 
yapatite column chromatography. Consistent with 
the immunological studies, two distinct enzyme 
fractions were eluted from the hydroxyapatite col- 
umn at approx. 100 and 150 mM potassium 
phosphate, which corresponded to type II (0) and 
type III (cu) PKC, respectively (fig.3). Im- 
munoblotting analysis indicated that type II con- 
sists of mainly@II-PKC, with little, if anypI-PKC. 
In the control cells PKC was found in the 
cytoplasmic but not the particulate fraction 
(fig.3A,G). After TPA treatment type II and type 
III PKC in the cytosol were rapidly decreased. 
Type II was translocated to the particulate fraction 
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(approx. 15% of the activity in the untreated 
cytoplasmic fraction) at 2 min (fig.3B,H). At 
15 min, type II PKC had disappeared in both solu- 
ble and particulate fractions, whereas type III PKC 
translocation to the particulate fraction had reach- 
ed the maximum level (approx. 20% of the type III 
PKC activity in the untreated cytoplasmic fraction) 
(fig.3D,J). At 3 h, a small amount of type III PKC 
(approx. 1%) remained in the particulate fraction 
(fig.3K), and at 6 h there was no detectable PKC 
in any fractions (fig.3F,L). These profiles are more 
quantitatively plotted in fig.4. 
During the entire time course examined, a Ca’+-, 
phospholipid- and diacylglycerol-independent pro- 
tein kinase activity was slightly increased in the 
soluble fraction with the maximum value at 15 min 
(approx. 20% of that activity in the untreated con- 
trol cells). However, definitive evidence was 
unavailable indicating that this activity is due to 
protein kinase M, a proteolytically produced 
catalytic fragment of PKC [7]. 
4. DISCUSSION 
Previous studies have shown that treatment with 
TPA elicits translocation and down-regulation 
(depletion) of PKC in a variety of cell types [5,6]. 
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Fig.3. Translocation and down-regulation of PKC subspecies in 
KM3 cells. KM3 cells were treated with 50 nM TPA for the 
indicated times. PKC subspecies were resolved and assayed as 
described in section 2. Activity of PKC subspecies in (A-F) 
cytoplasmic and (G-K) particulate fractions. (A,G) At time 0, 
(B,H) 2 min. (C.1) 5 min; (D,J) 15 min, (E,K) 180 min, (F,L) 
240 min after TPA treatment. PKC activity in the presence of 
(e) phosphatidylserine, diolein and CaClz and of (0) EGTA 
instead of phosphatidylserine, diolein and CaClz. 
The results presented above show that, when 
treated with TPA, PKC subspecies co-expressed in 
a single cell, KM3, are apparently translocated to 
the particulate fraction and subsequently depleted 
at different rates. This depletion of PKC molecules 
appears to be initiated by the action of calpain I, 
since this protease cleaves preferentially the active 
form, but not the inactive resting form of PKC [7]. 
Recent analysis in this laboratory indicates that the 
limited proteolysis of PKC takes place at a site in 
the third variable region, V3 [21], which connects 
the regulatory and protein kinase domains 
(Kishimoto et al., unpublished). Consistent with 
the observation described here, type II PKC is 
more susceptible to calpain I than type III PKC 
TIME (MIN) 
Fig.4. Time course of translocation and down-regulation of 
PKC subspecies in KM3 cells. KM3 cells were treated with TPA, 
and PKC activity in each fraction was analyzed as described in 
fig.3. (A) Type II, (B) type 111; PKC activity of (A ,o) 
cytoplasmic and (11 (3) particulate fractions. 
under comparable conditions. 
The limited proteolysis of PKC may generate a 
fragment of PKC of approx. 51 kDa, protein 
kinase M, which is fully active, in vitro, without 
added Ca’+, phospholipid, and diacylglycerol [7]. 
Two alternative possibilities for the significance of 
this mechanism have thus far been discussed; first- 
ly, that this proteolysis is a process to activate PKC 
and that the resulting fragment may play some 
roles in the control of cellular functions [9,22]; and 
secondly, that this is a process for initiating the 
degradation of PKC, eventually leading to its 
disappearance, termed down-regulation [6,23). 
However, at present, no obvious evidence is 
available to support the first possibility. Upon 
treatment of KM3 cells with TPA, Ca*+-, 
phospholipid- and diacylglycerol-independent pro- 
tein kinase activity was slightly increased in the 
cytoplasmic fraction as noted above. However, all 
biochemical and immunological approaches have 
failed to identify this activity as protein kinase M. 
Rather, it is worth noting that the total protein 
kinase activity originally found in intact KM3 cells 
is rapidly depleted and disappears after treatment 
with TPA. It is attractive to investigate further 
whether the limited proteolysis by calpain I does 
initiate the down-regulation of various PKC 
molecules. 
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